France: Polyplus sale earns 300 times return on investment for Archimed

Sartorius’ agreement to acquire Polyplus for €2.4bn (US$2.65bn), is set to realise Private Equity investor, Archimed, an massive 300 times return on its original investment. German life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, signed an agreement to acquire Polyplus, a broad-based upstream bioprocessing player, from private investors including Archimed and…

You must be a HMI Subscriber to view this content.

Subscribe Now »